Lower-dosing ponatinib in pre-treated GIST: Results of the POETIG phase II trial.

11536Background: Despite long-lasting responses to imatinib most metastatic gastrointestinal stromal tumors (GIST) eventually progress and subsequent treatments are associated with limited duration...